The Role of Allele Blast in Myeloprolysm

This is turning out to be a very useful biomarker of the disease. It reflects both clinical burden but prognosis for venous thrombotic events and also prognosis for progression. And that this is also a dynamic marker that can be measured over time. We now have targeted therapies in many ways, as Dr. Malali mentioned, for myeloplifer disease. This really matters what your mutational driver is. There are better jack inhibitors or stronger jack inhibitors coming on. I think we need stop referring to Philadelphia chromosome negative myeloprolative disorders. But again as mutant positive disease positive disease.